Show results for
Refine by
Small Molecule Drug Equipment & Supplies In Iran
12 equipment items found
Manufactured by:Acousia Therapeutics GmbH based inTübingen, GERMANY
With its first clinical study underway, Acousia is taking significant strides towards achieving its goal of developing novel medicines that enhance and preserve natural hearing for patients with ...
Manufactured by:Gerresheimer AG based inDüsseldorf, GERMANY
The on-body infusor for the subcutaneous application of small-molecule drugs is available for volumes up to 3 ml. It can be worn on the body. Typical applications are bolus and basal regimens over several ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
Traditionally, many small molecule drugs follow the same basic mechanism of action to treat diseases: They inhibit the function of a target protein that has an active role in a disease. To do so, they require a tractable active binding site to occupy, which will result in protein function inhibition like blocking its enzymatic activity. But ...
Manufactured by:Gerresheimer AG based inDüsseldorf, GERMANY
This belt-worn on-body drug delivery device for small-molecule drugs has been developed for our pharma partner EVER Pharma. The wearable device is used by Parkinson's disease patients for the administration of apomorphine to treat this long-term degenerative disorder of the central nervous system. This device is customizable to ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, radioisotopes). This flexibility has allowed Starpharma to develop a range of DEP® radiotheranostics as well as its other DEP® programs. ...
Manufactured by:Krieger AG based inMuttenz, SWITZERLAND
With a starting minimum volume of 25 ml, the Micro Mixer range is the ideal tool to scale down your contained mixing processes under pressure or vacuum. Dissolution of expensive shear sensitive API's, proteins, Developing and processing small molecule and complex biologic drug candidates. Or just vacuum ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Peptides are an increasingly important class of drug. As natural ligands to many targets, they can combine agonistic or antagonistic activity with low toxicity risk and can be applied to disease targets, where small molecules or antibody-based drugs cannot be used. However, the number of therapeutic peptide drugs ...
Manufactured by:Bexson Biomedical based inSanta Barbara, CALIFORNIA (USA)
Pharmaceutical technology for liquid formulations. A patented 7-Valence Salt revolutionizing small molecule ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and Starpharma has a number of partner programs in the area. ...
by:AdAlta Limited based inBundoora, AUSTRALIA
An i-body is a human protein that belongs to the class of next generation antibodies. The i-body is built on the scaffold of a human protein and engineered with two loops that mimic the shape of shark antibodies. These loops are responsible for binding or interacting with a particular target (in circulation or on a cell) that is causing disease. i-bodies are identified and developed using our ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new disease targets with Dr.UG and further realizes precision medicine by designing small molecules for ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...